Rovin BH, et al. Lancet 2023; 402: 2077–2090
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
Grandangolo in Nefrologia, Dialisi e Trapianto
Newsletter
©Accademia Nazionale di Medicina | Provider ECM Nazionale N° 31 | Tutti i diritti riservati | Webmaster | Privacy policy | Powered by Forum Service